NCT04938297View on ClinicalTrials.gov

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2025

Conditions
Central Nervous System Lymphoma
Interventions
DRUG

Rituximab, Lenalidomide, Zanubrutinib

Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.

DRUG

Lenalidomide, Zanubrutinib

Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression

DRUG

Lenalidomide

Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression

Trial Locations (1)

Unknown

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV